- Home
- FISI vs LRMR Comparison
FISI vs LRMR Comparison
Compare FISI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- LRMR
- Stock Information
- Founded
- FISI 1817
- LRMR N/A
- Country
- FISI United States
- LRMR United States
- Employees
- FISI N/A
- LRMR N/A
- Industry
- FISI Major Banks
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- FISI Finance
- LRMR Health Care
- Exchange
- FISI Nasdaq
- LRMR Nasdaq
- Market Cap
- FISI 416.4M
- LRMR 426.9M
- IPO Year
- FISI 1999
- LRMR N/A
- Fundamental
- Price
- FISI $27.46
- LRMR $6.13
- Analyst Decision
- FISI Hold
- LRMR Strong Buy
- Analyst Count
- FISI 2
- LRMR 8
- Target Price
- FISI $22.00
- LRMR $19.63
- AVG Volume (30 Days)
- FISI 41.2K
- LRMR 755.1K
- Earning Date
- FISI 10-24-2024
- LRMR 10-30-2024
- Dividend Yield
- FISI 4.44%
- LRMR N/A
- EPS Growth
- FISI N/A
- LRMR N/A
- EPS
- FISI 3.17
- LRMR N/A
- Revenue
- FISI $216,605,000.00
- LRMR N/A
- Revenue This Year
- FISI N/A
- LRMR N/A
- Revenue Next Year
- FISI $6.94
- LRMR N/A
- P/E Ratio
- FISI $8.66
- LRMR N/A
- Revenue Growth
- FISI 9.25
- LRMR N/A
- 52 Week Low
- FISI $16.29
- LRMR $3.19
- 52 Week High
- FISI $28.12
- LRMR $13.68
- Technical
- Relative Strength Index (RSI)
- FISI 60.29
- LRMR 36.77
- Support Level
- FISI $26.00
- LRMR $5.92
- Resistance Level
- FISI $28.12
- LRMR $6.60
- Average True Range (ATR)
- FISI 0.73
- LRMR 0.70
- MACD
- FISI 0.05
- LRMR -0.30
- Stochastic Oscillator
- FISI 85.10
- LRMR 11.78
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.